stocks logo

ENVB

Enveric Biosciences Inc
$
1.310
-0.01(-0.758%)1D
  • Overview
  • Forecast
  • Valuation
  • Earnings
Line
Line
|
Candle
Candle
1D
5D
1M
3M
6M
YTD
1Y
5Y
High
1.340
Open
1.340
VWAP
1.29
Vol
82.86K
Mkt Cap
3.24M
Low
1.265
Amount
106.94K
EV/EBITDA(TTM)
--
Total Shares
7.75M
EV
-1.06M
EV/OCF(TTM)
--
P/S(TTM)
--
Enveric Biosciences, Inc. is a biotechnology company. The Company is engaged in the development of neuroplastogenic small-molecule therapeutics for the treatment of depression, anxiety, and addiction disorders. Leveraging its discovery and development platform, the Psybrary platform, which houses proprietary information on the use and development of existing and novel molecules for specific mental health indications, the Company seeks to develop a robust intellectual property portfolio of drug candidates. Its lead molecule, EB-003, is a neuroplastogen designed to promote neuroplasticity, without inducing hallucinations, in patients suffering from difficult-to-address mental health disorders. The Company is focused on advancing EB-003 towards clinical trials for the treatment of neuropsychiatric disorders while out-licensing other Psybrary platform drug candidates to third-party licensees and advancing non-competitive market strategies for patient care.
Show More

Valuation Metrics

The current forward P/E ratio for Enveric Biosciences Inc (ENVB.O) is -1.53, compared to its 5-year average forward P/E of -1.48. For a more detailed relative valuation and DCF analysis to assess Enveric Biosciences Inc 's fair value, click here.

Forward PE

StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-1.48
Current PE
-1.53
Overvalued PE
0.48
Undervalued PE
-3.43

Forward EV/EBITDA

StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
0.07
Current EV/EBITDA
0.15
Overvalued EV/EBITDA
0.32
Undervalued EV/EBITDA
-0.19

Forward PS

StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
0.00
Current PS
0.00
Overvalued PS
0.00
Undervalued PS
0.00

Financials

Annual
Quarterly
FY2025Q1
N/A
Total Revenue
FY2025Q1
YoY :
-11.70%
-2.19M
Operating Profit
FY2025Q1
YoY :
-11.07%
-2.18M
Net Income after Tax
FY2025Q1
YoY :
-86.75%
-1.22
EPS - Diluted
FY2025Q1
YoY :
-100.00%
N/A
Free Cash Flow
FY2025Q1
N/A
Gross Profit Margin - %
FY2025Q1
N/A
FCF Margin - %
FY2025Q1
N/A
Net Margin - %

Trading Trends

Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
0-3
Months
0.0
Volume
0
3-6
Months
0.0
Volume
0
6-9
Months
0.0
Volume
0
0-12
Months
0.0
Volume
0
Bought
0-3
0
0.0
Volume
Months
3-6
0
0.0
Volume
Months
6-9
0
0.0
Volume
Months
0-12
0
0.0
Volume
Months
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months

ENVB News & Events

Events Timeline

2025-07-23 (ET)
2025-07-23
08:51:37
Enveric Biosciences receives second notice of allowance from USPTO for EVM401
select
2025-07-15 (ET)
2025-07-15
09:36:40
Enveric Biosciences announces results of EB-003 preclinical model
select
2025-06-24 (ET)
2025-06-24
09:22:08
Enveric announces data broadening clinical potential for lead candidate
select
Sign Up For More Events

News

9.0
07-23Newsfilter
Enveric Biosciences Secures Second U.S. Patent Allowance for Next-Generation, Non-Hallucinogenic Mescaline Derivatives in EVM401 Series
3.5
07-20Yahoo Finance
Weekly Roundup on the Cannabis Sector & Psychedelic Sector
9.0
07-15Newsfilter
Enveric Biosciences Lead Drug Candidate EB-003 Demonstrates Positive Effects in Preclinical Model of Post-Traumatic Stress Disorder (PTSD)
Sign Up For More News

FAQ

arrow icon

What is Enveric Biosciences Inc (ENVB) stock price today?

The current price of ENVB is 1.31 USD — it has decreased -0.76 % in the last trading day.

arrow icon

What is Enveric Biosciences Inc (ENVB)'s business?

arrow icon

What is the price predicton of ENVB Stock?

arrow icon

What is Enveric Biosciences Inc (ENVB)'s revenue for the last quarter?

arrow icon

What is Enveric Biosciences Inc (ENVB)'s earnings per share (EPS) for the last quarter?

arrow icon

What changes have occurred in the market's expectations for Enveric Biosciences Inc (ENVB)'s fundamentals?

arrow icon

How many employees does Enveric Biosciences Inc (ENVB). have?

arrow icon

What is Enveric Biosciences Inc (ENVB) market cap?